Allen Institute's immunology division launches with $125M, Lilly vet and five partners

The Allen Institute expects its latest research endeavor to generate knowledge about molecular drivers of immune-related diseases, paving the way for new diagnostics and therapies. The Allen Institute for Immunology launched Wednesday with $125 million from the late Allen Institute founder Paul Allen and tapped Eli Lilly and Co. (NYSE:LLY) drug discovery veteran Thomas Bumol as executive director.

Bumol contributed to drug discovery and early clinical development across several immune-related diseases at Lilly. He was SVP of Lilly Research Laboratories' biotechnology and immunology research business and site head of Lilly's biotech center in San Diego...